Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$88.81 USD

88.81
906,353

-0.19 (-0.21%)

Updated Oct 28, 2024 12:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Mark Vickery headshot

Top Research Reports for Mastercard, Gilead & Goldman Sachs

Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Gilead (GILD) and Goldman Sachs (GS).

    Ryan McQueeney headshot

    Why Biotech Stocks Rallied on Biogen's Alzheimer's Test

    Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.

      Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More

      Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.

        Is Gilead Sciences a Great Stock for Value Investors?

        Let's see if Gilead Sciences Inc. (GILD) stock is a good choice for value-oriented investors right now from multiple angles.

          Novartis to Spin-Off Alcon as Separate Trading Company

          Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.

            Gilead's (GILD) CAR T Therapy Gets Positive CHMP Opinion

            Gilead (GILD) obtains positive opinion from the CHMP for its MAA for CAR T therapy, axicabtagene ciloleucel, as a treatment for DLBCL and PMBCL.

              Ekta Bagri headshot

              4 Biotech Stocks to Bet on in the Second Half of 2018

              While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.

                Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod

                The biotech sector was in the news with a few hits and misses. Gilead's Biktarvy got approval in Europe while Puma Biotechology is also closer to breast cancer drug approval in Europe.

                  Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection

                  Gilead's (GILD) HIV portfolio gets a further boost with the European Commission's approval of Biktarvy for HIV-1 infection.

                    Kevin Cook headshot

                    CRISPR Science and Stocks: Knowing Enough to Invest

                    Can you learn enough about the science and the companies to invest with confidence?

                      Novartis Announces Positive Data on CAR-T Therapy, Kymriah

                      Novartis (NVS) announces positive results on Kymriah from the JULIET TRIAL in patients with relapsed or refractory diffuse large B-cell lymphoma.

                        Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

                        Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

                          Ekta Bagri headshot

                          NASH Space in Focus as Galmed (GLMD) Posts Positive Data

                          Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.

                            Tracey Ryniec headshot

                            Drug Stocks: The Next Hot Industry or Value Traps?

                            These 5 stocks look dirt cheap but is it too good to be true?

                              Galmed (GLMD) Soars on Positive NASH Data on Aramchol

                              Shares of Galmed Pharmaceuticals (GLMD) surges significantly following positive top-line results on lead candidate Aramchol in NASH patients.

                                Indrajit Bandyopadhyay headshot

                                JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space

                                Given the growing interest in JAK-inhibitor based treatments, here's a look at some companies that are looking to change the ways to treat autoimmune diseases.

                                  Gilead Collaborates with Hookipa for HBV and HIV Therapies

                                  Gilead Sciences (GILD) collaborates with Hookipa Biotech AG for the development of immunization technologies for HBV and HIV diseases.

                                    Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO

                                    The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.

                                      Madrigal's NASH Study Data Encouraging, Stock Skyrockets

                                      Madrigal Pharmaceuticals' (MDGL) thyroid hormone receptor, MGL-3196, achieves significantly sustained reduction in liver fat at week 36 in a phase II study evaluating it in NASH patients.

                                        Gilead & Galapagos Announce Positive Data on Filgotinib

                                        Gilead (GILD) and partner Galapagaos (GLPG) announces positive data on filgotinib for the treatment of psoriatic arthritis in adults and ulcerative colitis.

                                          Why Is Gilead Sciences (GILD) Down 7.2% Since Its Last Earnings Report?

                                          Gilead Sciences (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                            Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod

                                            The biotech sector grabbed headlines last week with drug approvals and licensing deals. Investors will await pipeline development news at the ASCO in the coming week.

                                              bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA

                                              bluebird (BLUE) obtained Breakthrough Therapy designation from the FDA for Lenti-D for the treatment of patients with cerebral adrenoleukodystrophy, which should expedite its development.

                                                Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval

                                                Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.

                                                  Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag

                                                  Intercept's (ICPT) first-quarter results were mixed as loss was narrower than expectations but sales missed expectations. The company also provided Ocaliva sales guidance for 2018.